Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.68 +10.3%	$2.28	$0.90 ▼ $2.96	$88.04M	0.99	9,296 shs	14,985 shs
CMPX Compass Therapeutics	$3.02 +7.9%	$2.84	$1.19 ▼ $4.08	$387.19M	1.49	1.37 million shs	1.45 million shs
CRVS Corvus Pharmaceuticals	$5.55 +4.9%	$4.37	$2.54 ▼ $10.00	$394.18M	0.42	466,447 shs	619,189 shs
VIGL Vigil Neuroscience	$8.05	$8.02	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	+10.29%	+5.10%	+11.67%	+41.80%	-26.78%
CMPX Compass Therapeutics	+7.86%	+1.68%	-9.31%	+44.50%	+153.78%
CRVS Corvus Pharmaceuticals	+4.91%	+2.21%	+18.84%	+59.03%	+33.73%
VIGL Vigil Neuroscience	0.00%	0.00%	-0.25%	+2.03%	+121.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	3.0738 of 5 stars	3.5	5.0	2.7	1.7	0.0
CMPX Compass Therapeutics	2.7146 of 5 stars	3.6	1.0	2.0	5.0	0.0
CRVS Corvus Pharmaceuticals	2.799 of 5 stars	3.5	2.0	1.8	3.3	0.6
VIGL Vigil Neuroscience	1.8497 of 5 stars	3.0	3.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	235.82% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	326.78% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	170.27% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside

Current Analyst Ratings Breakdown

Latest ARMP, VIGL, CRVS, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$5.17M	18.78	N/A	N/A	($1.92) per share	-1.40
CMPX Compass Therapeutics	$850K	491.30	N/A	N/A	$0.67 per share	4.51
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$18.92M	-$1.64	N/A	N/A	N/A	-374.30%	N/A	-24.00%	N/A
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	11/6/2025 (Estimated)

Latest ARMP, VIGL, CRVS, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.06	0.06
CMPX Compass Therapeutics	N/A	7.66	7.66
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
CMPX Compass Therapeutics	68.43%
CRVS Corvus Pharmaceuticals	46.64%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	84.50%
CMPX Compass Therapeutics	29.80%
CRVS Corvus Pharmaceuticals	28.50%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.23 million	5.62 million	Not Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

ARMP, VIGL, CRVS, and CMPX Headlines

Recent News About These Companies

Vigil Neuroscience Inc Merger and Leadership Changes

August 13, 2025 | theglobeandmail.com

Blair William & Co. IL Raises Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

August 10, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Recommendation of "Hold" from Brokerages

August 6, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Growth in Short Interest

August 3, 2025 | marketbeat.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

Vigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | Benzinga

May 24, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, VIGL, CRVS, and CMPX Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.68 +0.25 (+10.29%)

Closing price 08/22/2025 04:10 PM Eastern

Extended Trading

$2.59 -0.09 (-3.51%)

As of 08/22/2025 04:38 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Compass Therapeutics NASDAQ:CMPX

$3.02 +0.22 (+7.86%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.97 -0.05 (-1.66%)

As of 08/22/2025 07:55 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.55 +0.26 (+4.91%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.50 -0.05 (-0.90%)

As of 08/22/2025 06:39 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time